This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Clinimetric properties bronchiectasis v1.0

  • Research type

    Research Study

  • Full title

    BronchUK: Clinimetric Properties of Outcome Measures in Bronchiectasis in the UK

  • IRAS ID

    166832

  • Contact name

    Stuart Elborn

  • Contact email

    jselborn@doctors.org.uk

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    There is currently little agreement on the core clinical endpoints that should be used in bronchiectasis. The importance of improving endpoint outcome measurement is well recognised and groups in other conditions have focused on activities to achieve consensus on a core set of outcomes for clinical trials. The Bronch-UK collaboration has explored the current evidence for clinimetric properties of commonly used outcome measures in bronchiectasis (e.g. forced expiratory volume in one second [FEV1], health related quality of life [HRQoL], and pulmonary exacerbations). The results of this extensive rigorous literature review of 68 papers (Smith and Hill, 2012) clearly demonstrate that whilst there was good evidence for validity for key outcome measures in bronchiectasis there is little information available on their reliability (during periods of clinical stability) or response to treatment (effect sizes).

    The overall aim of this study is to ascertain the clinimetric properties of a range of outcome measures in order to make recommendations on their use in clinical trials in bronchiectasis. Our specific questions are which outcome measures are most stable in bronchiectasis over time; and, which outcome measures demonstrate the biggest effect size over a pulmonary exacerbation signal interval?

  • REC name

    HSC REC B

  • REC reference

    15/NI/0077

  • Date of REC Opinion

    21 May 2015

  • REC opinion

    Favourable Opinion